2012, Number 1
<< Back Next >>
Ann Hepatol 2012; 11 (1)
Budd-Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis
Mederacke I, Helfritz F, Puls F, Ringe KI , Klempnauer J, Manns MP, Strassburg CP
Language: English
References: 7
Page: 143-144
PDF size: 147.57 Kb.
Text Extraction
To the editor
Standard treatment of autoimmune hepatitis
(AIH) includes steroids such as predniso(lo)ne based
upon study data established decades ago. Pilot
studies indicate that budesonide may represent
an alternative treatment option.
REFERENCES
Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
Strassburg CP. Autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2010; 24: 667-82.
Wiegand J, Schuler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005; 25: 927-34.
Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-206.
Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994; 8: 585-90.
Hempfling W, Grunhage F, Dilger K, et al. Pharmacokinetics and pharmacodynamic action of budesonide in earlyand late-stage primary biliary cirrhosis. Hepatology 2003; 38: 196-202.
Plessier A, Valla DC. Budd-Chiari syndrome. Semin Liver Dis 2008; 28: 259-69.
Full text